Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVARTIS AG : Sell rating from Barclays

share with twitter share with LinkedIn share with facebook
09/23/2020 | 09:04am EDT

Barclays reiterate its Sell rating. The target price is unchanged and still at CHF 75.

© MarketScreener with dpa-AFX Analyser 2020

Stocks mentioned in the article
ChangeLast1st jan.
BARCLAYS PLC 1.19% 105.5 Delayed Quote.-41.93%
NOVARTIS AG -0.99% 77 Delayed Quote.-15.38%
share with twitter share with LinkedIn share with facebook
All news about NOVARTIS AG
01:40aNOVARTIS : receives US Food and Drug Administration (FDA) Orphan Drug Designatio..
PU
10/19AEQUUS PHARMACEUTICALS : Extends Commercial Agreement for Specialty Product Tacr..
AQ
10/16NOVARTIS : Genmab to Host Capital Markets Day
AQ
10/15Genmab Announces Data to be presented at SITC 35th Anniversary Annual Meeting
AQ
10/14NOVARTIS AG : UBS keeps its Buy rating
MD
10/13NOVARTIS AG : Goldman Sachs gives a Buy rating
MD
10/12NOVARTIS : received European Medicines Agency PRIME designation for iptacopan in..
AQ
10/09NOVARTIS AG : JP Morgan reiterates its Sell rating
MD
10/09NOVARTIS : received European Medicines Agency (EMA) PRIME designation for iptaco..
PU
10/08NOVARTIS : Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
More news
Financials (USD)
Sales 2020 49 678 M - -
Net income 2020 8 901 M - -
Net Debt 2020 18 823 M - -
P/E ratio 2020 20,6x
Yield 2020 3,68%
Capitalization 189 B 189 B -
EV / Sales 2020 4,18x
EV / Sales 2021 3,83x
Nbr of Employees 110 000
Free-Float 86,9%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 107,66 $
Last Close Price 85,75 $
Spread / Highest target 62,9%
Spread / Average Target 25,6%
Spread / Lowest Target -3,82%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-15.38%188 853
JOHNSON & JOHNSON-0.90%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-3.52%210 050
MERCK & CO., INC.-13.94%198 975
NOVO NORDISK A/S16.68%166 008